No Link — a 20% price control is optimal, increasing access without decreasing profits.
Moshe Levy , business professors, Hebrew University, 2014, [School of Business, The Hebrew University, Jerusalem, Israel; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113894]
We find that mild price regulation can substantially increase consumer surplus and the number of patients using the drug, while having only a second-order effect of the revenues of the pharmaceutical companies. For example, setting the price cap at 20% lower than the optimal monopolistic price increases the consumer surplus by about 10%, and increases the number of patients using the drug by about 23%. This increase in the number of users almost completely offsets the adverse effect of the price regulation from the perspective of the pharmaceutical company – its revenues decrease by only about 1 percent
And this evidence only assumes the demand created by a lower drug price, it doesn’t even account for the increased demand created by more coverage
And their evidence is just speculative and written by hacks. Empirical evidence proves no long-